O'Donnell, Jake S, Hunt, Stewart K and Chappell, Keith J (2023). Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. The Lancet Haematology, 10 (7), e539-e548. doi: 10.1016/S2352-3026(23)00087-X
Journal Article: Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine
O’Donnell, Jake S., Isaacs, Ariel, Jakob, Virginie, Lebas, Celia, Barnes, James B., Reading, Patrick C., Young, Paul R., Watterson, Daniel, Dubois, Patrice M., Collin, Nicolas and Chappell, Keith J. (2022). Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. Frontiers in Immunology, 13 976968. doi: 10.3389/fimmu.2022.976968
Journal Article: Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?
O’Donnell, Jake S. and Chappell, Keith J. (2021). Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?. Frontiers in Microbiology, 12 724654, 1-4. doi: 10.3389/fmicb.2021.724654
O'Donnell, Jake S, Hunt, Stewart K and Chappell, Keith J (2023). Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. The Lancet Haematology, 10 (7), e539-e548. doi: 10.1016/S2352-3026(23)00087-X
Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine
O’Donnell, Jake S., Isaacs, Ariel, Jakob, Virginie, Lebas, Celia, Barnes, James B., Reading, Patrick C., Young, Paul R., Watterson, Daniel, Dubois, Patrice M., Collin, Nicolas and Chappell, Keith J. (2022). Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. Frontiers in Immunology, 13 976968. doi: 10.3389/fimmu.2022.976968
Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?
O’Donnell, Jake S. and Chappell, Keith J. (2021). Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?. Frontiers in Microbiology, 12 724654, 1-4. doi: 10.3389/fmicb.2021.724654
Lepletier, Ailin, Madore, Jason, O'Donnell, Jake S., Johnston, Rebecca L., Li, Xian-Yang, McDonald, Elizabeth, Ahern, Elizabeth, Kuchel, Anna, Eastgate, Melissa, Pearson, Sally-Ann, Mallardo, Domenico, Ascierto, Paolo A., Massi, Daniela, Merelli, Barbara, Mandala, Mario, Wilmott, James S., Menzies, Alexander M., Leduc, Charles, Stagg, John, Routy, Bertrand, Long, Georgina V., Scolyer, Richard A., Bald, Tobias, Waddell, Nicola, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2020). Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clinical Cancer Research, 26 (14), 3671-3681. doi: 10.1158/1078-0432.ccr-19-3925
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
Chew, Hui Yi, De Lima, Priscila O., Gonzalez Cruz, Jazmina L., Banushi, Blerida, Echejoh, Godwins, Hu, Lingbo, Joseph, Shannon R., Lum, Benedict, Rae, James, O'Donnell, Jake S., Merida de Long, Lilia, Okano, Satomi, King, Brigid, Barry, Rachael, Moi, Davide, Mazzieri, Roberta, Thomas, Ranjeny, Souza-Fonseca-Guimaraes, Fernando, Foote, Matthew, McCluskey, Adam, Robinson, Phillip J., Frazer, Ian H., Saunders, Nicholas A., Parton, Robert G., Dolcetti, Riccardo, Cuff, Katharine, Martin, Jennifer H., Panizza, Benedict, Walpole, Euan ... Simpson, Fiona (2020). Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 180 (5), 895-914.e27. doi: 10.1016/j.cell.2020.02.019
The promise of neoadjuvant immunotherapy and surgery for cancer treatment
O'Donnell, Jake S., Hoefsmit, Esmee P., Smyth, Mark J., Blank, Christian U. and Teng, Michele W.L. (2019). The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clinical Cancer Research, 25 (19), 5743-5751. doi: 10.1158/1078-0432.CCR-18-2641
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, Jake S., Teng, Michele W. L. and Smyth, Mark J. (2019). Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 16 (3), 151-167. doi: 10.1038/s41571-018-0142-8
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Liu, Jing, O’Donnell, Jake S., Yan, Juming, Madore, Jason, Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2019). Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. OncoImmunology, 8 (5) e1581530, 1-12. doi: 10.1080/2162402X.2019.1581530
Ahern, Elizabeth, Harjunpää, Heidi, O'Donnell, Jake S., Allen, Stacey, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2018). RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology, 7 (6) e1431088, e1431088. doi: 10.1080/2162402X.2018.1431088
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, Jing, Rozeman, Elisa A., O’Donnell, Jake S., Allen, Stacey, Fanchi, Lorenzo, Smyth, Mark J., Blank, Christian U. and Teng, Michele W. L. (2018). Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. OncoImmunology, 8 (2) e1546068, 1-10. doi: 10.1080/2162402X.2018.1546068
Glodde, Nicole, Bald, Tobias, van den Boorn-Konijnenberg, Debby, Nakamura, Kyohei, O'Donnell, Jake S., Szczepanski, Sabrina, Brandes, Maria, Eickhoff, Sarah, Das, Indrajit, Shridhar, Naveen, Hinze, Daniel, Rogava, Meri, van der Sluis, Tetje C., Ruotsalainen, Janne J., Gaffal, Evelyn, Landsberg, Jennifer, Ludwig, Kerstin U., Wilhelm, Christoph, Riek-Burchardt, Monika, Müller, Andreas J., Gebhardt, Christoffer, Scolyer, Richard A., Long, Georgina V., Janzen, Viktor, Teng, Michele W. L., Kastenmüller, Wolfgang, Mazzone, Massimiliano, Smyth, Mark J., Tüting, Thomas and Hölzel, Michael (2017). Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 47 (4), 789-802. doi: 10.1016/j.immuni.2017.09.012
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
O'Donnell, Jake S., Massi, Daniela, Teng, Michele W. L. and Mandala, Mario (2017). PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Seminars in Cancer Biology, 48, 91-103. doi: 10.1016/j.semcancer.2017.04.015
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, Jake S., Long, Georgina V., Scolyer, Richard A., Teng, Michele W. L. and Smyth, Mark J. (2017). Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 52, 71-81. doi: 10.1016/j.ctrv.2016.11.007
Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease
Liu, Jing, Blake, Stephen J., Yong, Michelle C. R., Harjunpaa, Heidi, Ngiow, Shin Foong, Takeda, Kazuyoshi, Young, Arabella, O'Donnell, Jake S., Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2016). Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery, 6 (12), 1382-1399. doi: 10.1158/2159-8290.CD-16-0577
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
O'Donnell, Jake S., Smyth, Mark J. and Teng, Michele W. L. (2016). Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. Genome Medicine, 8 (1) 111, 1-3. doi: 10.1186/s13073-016-0365-1
The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer
Pera, Elena, Kaemmerer, Elke, Milevskiy, Michael J. G., Yapa, Kunsala T. D. S., O'Donnell, Jake S., Brown, Melissa A., Simpson, Fiona, Peters, Amelia A., Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2016). The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell International, 16 (24) 24, 24. doi: 10.1186/s12935-016-0299-0
de Oliveira, A. Lepletier, Madore, J., O'donnell, S., Johnston, R. L., Eastgate, M., Mallardo, D., Ascierto, P. A., Massi, D., Merelli, B., Mandala, M., Wilmott, J. S., Bald, T., Stagg, J., Routy, B., Long, G. V., Scolyer, R. A., Waddell, N., Dougall, W. C., Teng, M. W. L. and Smyth, M. (2019). Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155. Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11-14 December 2019. Oxford, United Kingdom: Oxford University Press.
Kaemmerer, Elke, Pere, Elena, Peters, Amelia A., Yapa, Kunsala T. D. S., Simpson, Fiona, O'Donnell, Jake, Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2015). Calcium signalling and the acquisition of trastuzumab resistance in HER2 positive breast cancer cells. APSA ASCEPT Joint Scientific Meeting 2015, Hobart, TAS Australia, 29 November - 2 December 2015.